Navigation Links
Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
Date:12/1/2009

statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the operation of the global collaboration with Bayer Schering Pharma, the efficacy, safety and intended utilization of our product candidates, including the BiTE antibody that is the subject of the agreement with Bayer Schering Pharma, the mode of action of BiTE antibodies, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and the future payment of milestone and royalty payments by Bayer Schering Pharma. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborat
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
2. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
3. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health, First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
4. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
5. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
6. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
7. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Volcano Corporation (Nasdaq: VOLC ), ... economic outcomes on a global basis by developing ... visualization, physiology diagnostics and therapies, said today that ... Healthcare conference on Tuesday, September 9. ... and chief executive officer, will begin at 11:10 ...
(Date:9/2/2014)... , Sept. 2, 2014  VentiRx Pharmaceuticals, ... to the development and commercialization of novel ... an update on corporate and clinical activities ... for future funding, ongoing clinical trials and ... In corporate news, Chief Executive Officer Robert ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced that the U.S. Food and ... designation to the investigation of motolimod (VTX-2337) ... doxorubicin (PLD) for the treatment of women ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3
... 5, 2011 Reportlinker.com announces that ... available in its catalogue: ... Cosmetic Surgery, Facial Aesthetic and Medical ... http://www.reportlinker.com/p0610527/Emerging-Markets-Chinese-and-Indian-Cosmetic-Surgery-Facial-Aesthetic-and-Medical-Laser-Markets-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply The ...
... 2011 The Board of Directors of MSA (NYSE: ... a Vice President of the company, responsible for Global Product ... of November 1, will assume the role of President of ... (MEZ).  In his new role, Dr. Muschter will become a ...
Cached Medicine Technology:Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 2Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 3Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 4Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 5Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 6Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 7Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 8Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 9Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 10Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 11Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 12Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 13Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 14Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 15Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 16Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 17Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 18MSA Elects Dr. Thomas Muschter to Vice President 2
(Date:9/2/2014)... How well patients recover from cancer surgery may ... and the operations themselves. Family conflicts and other ... complications, a Mayo Clinic study has found. Addressing ... patients, stress, speed their recoveries and save health ... looked at colon cancer patients, and found that ...
(Date:9/2/2014)... suggests that the key to more youthful immune function ... report published in the Journal of Leukocyte ... lungs of old mice had different responses to ... these changes were reversed by ibuprofen. , "Inflammation in ... said Joanne Turner, Ph.D., a researcher involved in the ...
(Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
(Date:9/2/2014)... 02, 2014 Nanomedicine is essentially ... diagnosing, treating and/or prevention of diseases and infections. ... cardiovascular, neurological, and oncology diseases. , Nanomedicine ... to various nanoparticles, their medical usages, and their ... considerable scope for research in this domain, and ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present ... vida! Get Up! Get Moving!®. This event promotes Hispanic family ... for people of all ages and all sizes. The event, ... held at Kiest Park Recreation Center, 3080 S. Hampton Road, ... “Since 2007, we have partnered with National Alliance for Hispanic ...
Breaking Medicine News(10 mins):Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... Will Continue to be Used in Early ... from Decision Resources, WALTHAM, Mass., Oct. ... leading research and advisory firms focusing on ... is currently the leading biologic for Crohn,s ...
... 1, 2008 at this year,s liver ... SAN FRANCISCO, Oct. 27 Researchers analyzed 43,497,patients ... 22,863 adults,who received transplantation to determine the best time ... caused by differences in donor type was vastly offset ...
... 27 ReachMD XM 157 announces a new,"Medical ... receptor,antagonist and its effects on management of euvolemic ... XM 157, the first and only network for ... the Tide Against,Hyponatremia" four times a day October ...
... NORWALK, Conn., Oct. 27 Maclaren USA Inc.,announces the ... Chief Operation Officer., "Maclaren,s growth has been extraordinary ... our new from-birth transport system, the Grand Tour(TM),LX, is ... proven themselves to be exceptional leaders in their field. ...
... has donated a portable Automatic External Defibrillator (AED) to Habitat ... ... Newtown, Pennsylvania (PRWEB) October 27, 2008 -- HeartSine Technologies, ... donated a portable Automatic External Defibrillator (AED) to Habitat for ...
... reduced inflammation, cholesterol and belly fat , , SUNDAY, Oct. ... diet." , New research ties eating tart cherries ... weight and fat -- all major risk factors for ... presented by University of Michigan researchers at the American ...
Cached Medicine News:Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 3Health News:Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival 2Health News:ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia 2Health News:ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia 3Health News:Maclaren Appoints New President and New Chief Operation Officer 2Health News:HeartSine Portable Defibrillator Donation Brings Added Safety to Habitat for Humanity of Charlotte ReStore Location 2Health News:Cherry-Enriched Diet Cut Heart Risks in Rats 2
... KIMBERLY-CLARK BALLARD Adult TRACH ... in T-Piece, Elbow and Double ... separate from vials; 12 vials ... Offers multiple tracheostomy sizes, French ...
... KIMBERLY-CLARK BALLARD Adult TRACH ... designed and labeled for ... Features an isolated cleaning ... minimize potential for contamination ...
... Maxi-Flo® suction catheters ... or straight. , ... catheter kits are latex-free., ... feature a catheter tip ...
... are available with a single lumen or ... swivel, MDI adapter., ,Trac-Wedge™ device, and ... include a patient label. Dual swivel elbow ... All Portex® Steri-Cath® systems are latex-free. , ...
Medicine Products: